What is included in the evaluation prior to administering menopausal hormone replacement therapy (HRT)?

Answer

All candidates for HT should be thoroughly evaluated with a detailed history and complete physical examination for a proper diagnosis and identification of any contraindications.

Baseline laboratory and imaging studies before administering HT include the following:

Hemography
Urinalysis
Fasting lipid profile
Blood sugar levels
Serum estradiol levels: In women who will be prescribed an implant and in those whose symptoms persist despite use of an adequate dose of a patch or gel
Serum follicle-stimulating hormone (FSH) levels: To monitor women taking oral preparations for symptomatic control, especially those with premature menopause
Ultrasonography: To measure endometrial thickness and ovarian volume
Electrocardiography
Papanicolaou test
Mammography: Performed once every 2-3 years and annually after the age of 50 years

Endometrial sampling is not required in routine practice. However, the presence of abnormal bleeding before or during HT should prompt consideration of ultrasonography to check endometrial thickness (cutoff, < 4 mm), followed by outpatient Pipelle sampling and hysteroscopy. In women with a tight cervix, formal hysteroscopy and dilation and curettage under general anesthesia are advised.

Did this answer your question?

Yes No

Additional feedback? (Optional)

Thank you for your feedback!

La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002 Jun. 16(3):293-307. [Medline].
Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4. 293(23):1167-70. [Medline].
Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005 Jan 19. 293(3):330-9. [Medline]. [Full Text].
Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis?. J Bone Miner Res. 1992 Sep. 7(9):1005-10. [Medline].
Christiansen C. Sex steroids and the cardiovascular system. Osteoporos Int. 1997. 7 Suppl 1:S8-11. [Medline].
Kannel WB. New perspectives on cardiovascular risk factors. Am Heart J. 1987 Jul. 114(1 Pt 2):213-9. [Medline].
Pinkerton JV, Constantine GD. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey. Menopause. 2015 Dec 7. [Medline].
Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011 Jul. 86(7):673-80. [Medline]. [Full Text].
MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2001. CD002978. [Medline].
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006 Oct 18. CD001500. [Medline].
Khalili H, Higuchi LM, Ananthakrishnan AN, Manson JE, Feskanich D, Richter JM, et al. Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's Disease. Gastroenterology. 2012 Jul 27. [Medline].
Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20. 304(15):1684-92. [Medline].
Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med. 1999 Feb 16. 130(4 Pt 1):262-9. [Medline].
Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19. 356(16):1670-4. [Medline].
Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1. 290(13):1739-48. [Medline].
Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015 Mar 10. 3:CD002229. [Medline].
Seaman AM. Hormones Still Largely No Help to Heart After Menopause. Reuters Health Information. Available at http://www.medscape.com/viewarticle/841351. March 12, 2015; Accessed: June 17, 2015.
Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001 Mar 21. 285(11):1460-5. [Medline].
Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002 Apr 3. 94(7):497-504. [Medline].
Lacey JV Jr, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst. 2006 Oct 4. 98(19):1397-405. [Medline].
Kesslak JP. Can estrogen play a significant role in the prevention of Alzheimer's disease?. J Neural Transm Suppl. 2002. 227-39. [Medline].
Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004 Jun 23. 291(24):2959-68. [Medline].
Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002 Nov 6. 288(17):2123-9. [Medline]. [Full Text].
National Collaborating Centre for Women's and Children's Health (UK). Menopause. 2015 Nov 12. [Medline].
Nainggolan L. Menopause Therapy: 'Don't Suffer Silently,' Says UK NICE. Medscape Medical News. Available at http://www.medscape.com/viewarticle/854464#vp_1. November 13, 2015; Accessed: March 7, 2016.
de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Pérez S, Rees M, Yang C, et al. Revised Global Consensus Statement on Menopausal Hormone Therapy. Climacteric. 2016 Aug. 19 (4):313-5. [Medline].
Haelle T. New Menopause Guidelines Update HT Safety Evidence. Medscape Medical News. Available at http://www.medscape.com/viewarticle/867600. August 18, 2016; Accessed: September 20, 2016.
US Preventive Services Task Force., Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement. JAMA. 2017 Dec 12. 318 (22):2224-2233. [Medline].
Cahoon EK, Kitahara CM, Ntowe E, Bowen EM, Doody MM, Alexander BH, et al. Female Estrogen-Related Factors and Incidence of Basal Cell Carcinoma in a Nationwide US Cohort. J Clin Oncol. 2015 Dec 1. 33 (34):4058-65. [Medline].
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015 Jun. 12 (6):e1001833; discussion e1001833. [Medline].
Lewis R. Hormones Soon After Menopause Do Not Affect Cognition. Medscape Medical News. Available at http://www.medscape.com/viewarticle/845843. June 03, 2015; Accessed: March 7, 2016.
Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005 May. 105(5 Pt 1):1063-73. [Medline].
Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993 Oct 11. 153(19):2209-16. [Medline].
Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005 Feb 12. 330(7487):342. [Medline].
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 Aug 9. 362(9382):419-27. [Medline].
Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 Apr 30-May 6. 365(9470):1543-51. [Medline].
Brown T. Injectables, HRT products recalled for sterility concerns. Medscape Medical News. August 1, 2013. Available at http://www.medscape.com/viewarticle/808805. Accessed: August 13, 2013.
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1. 290(13):1729-38. [Medline].
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25. 289(24):3243-53. [Medline].
Clinical Synthesis Panel on HRT. Hormone replacement therapy. Clinical Synthesis Panel on HRT. Lancet. 1999 Jul 10. 354(9173):152-5. [Medline].
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15. 332(24):1589-93. [Medline].
Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004 Sep. 104(3):443-51. [Medline].
Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004 Jan. 15(1):100-4. [Medline].
Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2005 Apr 18. CD002229. [Medline].
Garton M. Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet. 2003 Oct 18. 362(9392):1328; author reply 1330-1. [Medline].
Glud E, Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med. 2004 Nov 8. 164(20):2253-9. [Medline].
Grady D. Postmenopausal hormones--therapy for symptoms only. N Engl J Med. 2003 May 8. 348(19):1835-7. [Medline].
Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000 May 2. 132(9):689-96. [Medline]. [Full Text].
Greer IA on behalf of the Royal College of Obstetricians and Gynaecologists. Hormone replacement therapy and venous thromboembolism. Guideline No. 19. Revised January 2004. Available at http://www.rcog.org.uk/womens-health/clinical-guidance/hormone-replacement-therapy-and-venous-thromboembolism-green-top-19.
Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003 May 8. 348(19):1839-54. [Medline]. [Full Text].
Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002 Feb 6. 287(5):591-7. [Medline].
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19. 280(7):605-13. [Medline]. [Full Text].
Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002 Jul 17. 288(3):334-41. [Medline].
Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003 Aug 7. 349(6):523-34. [Medline].
Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG. 2002 Dec. 109(12):1319-30. [Medline].
Mills PK, Riordan DG, Cress RD. Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. Gynecol Oncol. 2004 Oct. 95(1):215-25. [Medline].
Moorman PG, Schildkraut JM, Calingaert B, et al. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol. 2005 Jul. 193(1):76-82. [Medline].
Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. 2004 Jul. 82(1):186-95. [Medline].
Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28. 289(20):2663-72. [Medline].
Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19. 356(16):1670-4. [Medline].
Sit AS, Modugno F, Weissfeld JL, et al. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol. 2002 Aug. 86(2):118-23. [Medline].
Swegle JM, Kelly MW. Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May. 38(5):874-81. [Medline].
US Food and Drug Administration. Recall: firm press release. Beacon Hill Pharmacy d/b/a Rxtra Solutions issues voluntary nationwide recall of certain sterile products due to a question of sterility assurance [press release]. http://www.fda.gov/Safety/Recalls/ucm363284.htm. Available at http://July 31, 2013. Accessed: August 13, 2013.
van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Curr Med Chem. 2000 May. 7(5):499-517. [Medline].
Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003 May 28. 289(20):2673-84. [Medline].

Media Gallery

Stages/nomenclature of normal reproductive aging in women.

of 1

Author

Nicole K Banks, MD Assistant Professor of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine; Clinician, VCU Health

Nicole K Banks, MD is a member of the following medical societies: American College of Medical Genetics and Genomics, American Congress of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Chief Editor

Richard Scott Lucidi, MD, FACOG Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Suzanne R Trupin, MD, FACOG Clinical Professor, Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Urbana-Champaign; CEO and Owner, Women's Health Practice; CEO and Owner, Hada Cosmetic Medicine and Midwest Surgical Center

Suzanne R Trupin, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, International Society for Clinical Densitometry, AAGL, North American Menopause Society, American Medical Association, Association of Reproductive Health Professionals

Disclosure: Nothing to disclose.

Hemant Singhal, MD, MBBS, MBA, FRCS, FRCS(Edin), FRCSC Consultant Breast Surgeon, Clementine Churchill Hospital; Consultant Breast Surgeon, Harley Street Breast Clinic, UK

Hemant Singhal, MD, MBBS, MBA, FRCS, FRCS(Edin), FRCSC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of Edinburgh

Disclosure: Nothing to disclose.

Kanchan Kaur, MBBS, MS (GenSurg), MRCSEd Consulting Breast and Oncoplastic Surgeon, Medanta, The Medicity, India

Disclosure: Nothing to disclose.

Joan Pitkin, MBBS, FRCS, FRCOG Honorary Senior Clinical Lecturer, Faculty of Medicine, Imperial College; Consulting Staff, Northwick Park and St Mark's Hospitals, Northwest London Hospitals, NHS Trust; Director of Menopause Clinical and Research Unit, Director of Undergraduate Clinical Studies, Northwick Park and St Mark's Hospitals

Joan Pitkin, MBBS, FRCS, FRCOG is a member of the following medical societies: Royal Society of Medicine, International Continence Society, North American Menopause Society, British Menopause Society, International Menopause Society, International Urogynaecology Association, European Menopause and Andropause Society, United Kingdom Continence Society

Disclosure: Nothing to disclose.

What is included in the evaluation prior to administering menopausal hormone replacement therapy (HRT)?

Answer

Related Questions:

References

Tables

Contributor Information and Disclosures